Eledon Pharmaceuticals, Inc. Common Stock ELDN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-08T06:14:42.335Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:26:16.510345992Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-08T06:14:40.706703+00:00
Eledon Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.40 | 181.5% | 72.0% | 1.81 | 453.8% | 44.9% |
| 25Δ | 4.18 | 172.3% | 64.2% | |||
| 30Δ | 3.95 | 163.2% | 56.4% | |||
| 35Δ | 3.73 | 154.1% | 48.6% | |||
| 40Δ | 3.51 | 144.9% | 40.7% | 2.59 | 194.4% | 15.1% |
| 45Δ | 3.28 | 135.8% | 32.9% | 2.86 | 203.6% | 13.8% |
| 50Δ | 3.06 | 126.6% | 25.1% | 3.13 | 212.7% | 12.4% |
| 55Δ | 2.84 | 117.5% | 17.3% | 3.40 | 221.8% | 11.0% |
| 60Δ | 2.61 | 108.4% | 9.5% | 3.67 | 231.0% | 9.7% |
| 65Δ | 2.46 | 104.0% | 5.2% | 3.94 | 240.1% | 8.3% |
| 70Δ | 2.38 | 104.6% | 4.4% | 4.22 | 249.2% | 7.0% |
| 75Δ | 2.29 | 105.1% | 3.6% | 4.49 | 258.4% | 5.6% |
| 80Δ | 2.21 | 105.7% | 2.8% | 4.76 | 267.5% | 4.3% |
20Δ
- Pseudo strike
- 4.40
- IV
- 181.5%
- B/E move
- 72.0%
- Pseudo strike
- 1.81
- IV
- 453.8%
- B/E move
- 44.9%
25Δ
- Pseudo strike
- 4.18
- IV
- 172.3%
- B/E move
- 64.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 3.95
- IV
- 163.2%
- B/E move
- 56.4%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 3.73
- IV
- 154.1%
- B/E move
- 48.6%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.51
- IV
- 144.9%
- B/E move
- 40.7%
- Pseudo strike
- 2.59
- IV
- 194.4%
- B/E move
- 15.1%
45Δ
- Pseudo strike
- 3.28
- IV
- 135.8%
- B/E move
- 32.9%
- Pseudo strike
- 2.86
- IV
- 203.6%
- B/E move
- 13.8%
50Δ
- Pseudo strike
- 3.06
- IV
- 126.6%
- B/E move
- 25.1%
- Pseudo strike
- 3.13
- IV
- 212.7%
- B/E move
- 12.4%
55Δ
- Pseudo strike
- 2.84
- IV
- 117.5%
- B/E move
- 17.3%
- Pseudo strike
- 3.40
- IV
- 221.8%
- B/E move
- 11.0%
60Δ
- Pseudo strike
- 2.61
- IV
- 108.4%
- B/E move
- 9.5%
- Pseudo strike
- 3.67
- IV
- 231.0%
- B/E move
- 9.7%
65Δ
- Pseudo strike
- 2.46
- IV
- 104.0%
- B/E move
- 5.2%
- Pseudo strike
- 3.94
- IV
- 240.1%
- B/E move
- 8.3%
70Δ
- Pseudo strike
- 2.38
- IV
- 104.6%
- B/E move
- 4.4%
- Pseudo strike
- 4.22
- IV
- 249.2%
- B/E move
- 7.0%
75Δ
- Pseudo strike
- 2.29
- IV
- 105.1%
- B/E move
- 3.6%
- Pseudo strike
- 4.49
- IV
- 258.4%
- B/E move
- 5.6%
80Δ
- Pseudo strike
- 2.21
- IV
- 105.7%
- B/E move
- 2.8%
- Pseudo strike
- 4.76
- IV
- 267.5%
- B/E move
- 4.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 105.57% | |
| 150.61% | |
| 193.14% | |
| 130.66% | |
| 118.12% | |
| 120.56% | |
| 113.59% | |
| 111.09% |
Biotechnology
ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its…
More →ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to…
More →ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is…
More →ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Description unavailable
More →